secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2026-11-06T22:25:10+00:00
Accession:  0001493152-26-050533
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.07, 5.08, 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Mangoceuticals plans up to $10M Series D preferred Reg A offering; annual meeting set for Dec 30
--------------------------------------------------------------------------------

- Series B holder (all 50 shares) consented Nov 2, 2026 to 8% Series D Convertible Cumulative Preferred; up to 1,000,000 shares at $10.00 each via Regulation A offering.
- Neither the Series B Amendment nor the Series D certificate of designations has been filed with the Texas Secretary of State; neither is effective and the Company may not proceed.
- Series B Amendment recognizes Series D's senior dividend and liquidation rights and is limited to approving the Series D designation only.
- Combined 2025 and 2026 annual meeting set for Dec 30, 2026 at Dallas offices; record date Nov 12, 2026; shareholder proposals due Nov 16, 2026.
- No sales in the contemplated Regulation A offering will occur before the SEC qualifies the Form 1-A offering statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315226050533/0001493152-26-050533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315226050533/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-050533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer